STOCK TITAN

Lipocine (LPCN) SEC Filings

LPCN NASDAQ

Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.

The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.

Rhea-AI Summary

Lipocine Inc. (LPCN) Chief Executive Officer Mahesh V. Patel reported two direct purchases of common stock: 25,000 shares on November 12, 2026, at $1.5796 per share, and 25,000 shares on November 13, 2026, at $1.5999 per share. No Rule 10b5-1 plan is reported. Each transaction identifies Patel as the direct owner and records its own per-share price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
insider
-
Rhea-AI Summary

Lipocine Inc. dosed the first participant in BLOOM, its Phase 3 study of LPCN 1154 for postpartum depression. LPCN 1154 is an investigational product being developed as a 48-hour oral treatment intended for at-home use. The placebo-controlled outpatient study is expected to enroll approximately 120 participants.

BLOOM will assess change from baseline in the 17-item Hamilton Depression Rating Scale total score 60 hours after dosing begins, with topline results expected in 2H 2027. The study incorporates FDA feedback and strengthened site selection, eligibility assessments and data-quality controls after Lipocine’s prior Phase 3 trial did not meet its primary endpoint in the full analysis set. LPCN 1154 is not FDA-approved, and the study measures do not establish efficacy or assure a successful outcome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.56%
Tags
current report
-
Rhea-AI Summary

Lipocine Inc. reported third-quarter 2026 revenue of $2,290,072 for the quarter ended September 30, 2026, compared with $114,574 a year earlier, and a net loss of $666,192 versus $3,186,832. Diluted loss per share was $0.08, compared with $0.59. Unrestricted cash, cash equivalents and marketable investment securities were $21.5 million as of September 30, versus $14.9 million at December 31, 2025; the company reported approximately $28.5 million as of November 4, 2026, unaudited.

Lipocine announced the initiation of the BLOOM Phase 3 placebo-controlled outpatient study of LPCN 1154 for postpartum depression in September; it is expected to enroll approximately 120 participants. FDA feedback indicated the 505(b)(2) NDA package appeared complete except for a single positive and well-controlled Phase 3 trial. Health Canada approved TLANDO in September, and Verity Pharma plans a Canadian launch in early 2027. Pharmalink received UAE marketing authorization for TESTYRA in July and plans a launch there in early 2027.

Third-quarter revenue included $2.1 million of license and collaboration revenue and $190,000 in TLANDO royalties. Lipocine plans to submit a Phase 2 protocol for LPCN 2203 to the FDA; future studies are subject to resource prioritization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
current report
Rhea-AI Summary

Lipocine Inc. reported third-quarter 2026 revenue of $2,290,072, compared with $114,574 a year earlier, including $2,100,000 of license revenue. Net loss was $666,192, versus $3,186,832 in the prior-year quarter. For the first nine months of 2026, revenue was $2,599,568 and net loss was $6,960,681.

At September 30, cash and cash equivalents were $2,594,151 and marketable securities were $18,861,297. Lipocine believes its resources and interest will fund projected operations through at least November 5, 2027, but says it will need additional capital through equity or debt markets or out-licensing. It reported $13,471,794 in net proceeds from ATM stock sales during the nine months.

LPCN 1154 did not meet the primary endpoint in its Phase 3 trial, with results announced in April 2026. Lipocine has initiated the BLOOM Phase 3 study and anticipates enrolling 120 participants. Verity Pharma received Health Canada’s Notice of Compliance for TLANDO on September 29, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
quarterly report
-
Rhea-AI Summary

Lipocine Inc. (LPCN) updated the corporate presentation it uses in meetings with investors, analysts and others, and filed the presentation as an exhibit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
current report
-
Rhea-AI Summary

Lipocine Inc. announced that Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism). The approval was obtained through licensing partner Verity Pharmaceuticals Inc. (Verity Pharma), which holds exclusive commercial rights to TLANDO in North America and is responsible for regulatory and commercialization obligations in the United States and Canada. Verity is planning to launch and commercialize TLANDO in Canada by the end of 2026. More than 700,000 prescriptions are written annually in Canada for testosterone replacement therapy, and approximately 50% of this patient population is covered by private insurance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
current report
Rhea-AI Summary

Lipocine Inc. director John W. Higuchi reported two direct purchases of common stock, totaling 25,007 shares. He bought 9,037 shares at $2.15 per share on September 29, 2026, and 15,970 shares at $2.23 per share on September 30, 2026. No Rule 10b5-1 plan is reported for these purchases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
insider
-
Rhea-AI Summary

Lipocine Inc. (LPCN) director John W. Higuchi purchased 12,561 shares of common stock on September 28, 2026, at $2.16 per share; the transaction is described as a purchase in the open market or a private transaction. His directly held position after the purchase was 216,358 shares. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.91%
Tags
insider
-
Rhea-AI Summary

Lipocine Inc. (LPCN) filed a report stating that on September 16, 2026 it presented at the H.C. Wainwright 28th Annual Global Investor Conference in New York City, held September 14–16, 2026. The company furnished its conference presentation as Exhibit 99.1 and incorporated it by reference into this report.

The filing also lists a Cover Page Interactive Data File as Exhibit 104. No financial results, guidance, or transactional events are described; the disclosure centers on making Lipocine’s investor presentation publicly available to the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
current report
Rhea-AI Summary

Lipocine Inc. (LPCN) announced the initiation of BLOOM, a Phase 3 outpatient study of LPCN 1154, an oral brexanolone candidate for postpartum depression, with approximately 120 participants and first dosing expected in early Q4 2026. LPCN 1154 is being developed as a 48-hour, at-home treatment aimed at rapid symptom relief.

BLOOM incorporates U.S. FDA feedback and is designed to support a potential New Drug Application under the 505(b)(2) pathway, using the same dosing regimen and a HAM-D17 primary endpoint at 60 hours. The design adds site- and data-quality controls and prespecified sensitivity analyses, following a prior Phase 3 trial that did not meet its primary endpoint but showed exploratory efficacy signals when data from one anomalous high-enrolling site were excluded; those findings are described as exploratory and non-confirmatory. Lipocine reports $23.3 million in unrestricted cash, cash equivalents and marketable securities as of June 30, 2026 and expects existing resources to fund BLOOM, with anticipated average cash use of about $1 million per month during study execution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.20%
Tags
current report

FAQ

How many Lipocine (LPCN) SEC filings are available on StockTitan?

StockTitan tracks 71 SEC filings for Lipocine (LPCN), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Lipocine (LPCN)?

The most recent SEC filing for Lipocine (LPCN) was filed on November 13, 2026.